MLICM
CHRS icon

Metropolitan Life Insurance Company (MetLife)’s Coherus Oncology CHRS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,365
Closed -$5.65K – 420
2024
Q1 		$5.65K Sell
2,365
-414
-15% -$1.02K ﹤0.01% 2241
2023
Q4 		$9.25K Sell
2,779
-3,085
-53% -$8.26K ﹤0.01% 2203
2023
Q3 		$21.9K Buy
5,864
+1,811
+45% +$8.37K ﹤0.01% 1850
2023
Q2 		$17.3K Buy
+4,053
New +$23.9K ﹤0.01% 2008
2023
Q1 		– Sell
-4,249
Closed -$33.7K – 2336
2022
Q4 		$33.7K Hold
4,249
– – ﹤0.01% 1721
2022
Q3 		$40.8K Hold
4,249
– – ﹤0.01% 1596
2022
Q2 		$30.8K Hold
4,249
– – ﹤0.01% 1802
2022
Q1 		$54.9K Sell
4,249
-13,564
-76% -$172K ﹤0.01% 1543
2021
Q4 		$284K Hold
17,813
– – ﹤0.01% 1770
2021
Q3 		$286K Buy
+17,813
New +$261K ﹤0.01% 1814
2021
Q2 		– Sell
-15,893
Closed -$232K – 2737
2021
Q1 		$232K Sell
15,893
-1,896
-11% -$32.2K ﹤0.01% 1917
2020
Q4 		$309K Hold
17,789
– – ﹤0.01% 1664
2020
Q3 		$326K Sell
17,789
-2,505
-12% -$46.6K 0.01% 1491
2020
Q2 		$362K Hold
20,294
– – 0.01% 1436
2020
Q1 		$329K Buy
20,294
+343
+2% +$6.34K 0.01% 1306
2019
Q4 		$359K Sell
19,951
-794
-4% -$14.6K 0.01% 1532
2019
Q3 		$420K Buy
20,745
+3,674
+22% +$73.4K 0.01% 1403
2019
Q2 		$377K Hold
17,071
– – 0.01% 1485
2019
Q1 		$233K Hold
17,071
– – ﹤0.01% 1798
2018
Q4 		$154K Buy
17,071
+1,200
+8% +$13.9K ﹤0.01% 1982
2018
Q3 		$262K Buy
+15,871
New +$281K ﹤0.01% 1826
2015
Q4 		– Sell
-16,813
Closed -$337K – 2589
2015
Q3 		$337K Buy
+16,813
New +$512K ﹤0.01% 1904

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CHRS Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Coherus Oncology (CHRS) in Q2 2024, closing a stake of 2,365 shares — an estimated $5.65K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CHRS in Q3 2015 and held it in 22 quarters. The position peaked at $420K in Q3 2019. 135 funds tracked by Wall St. Rank hold CHRS as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Coherus Oncology position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,365 Coherus Oncology shares in Q2 2024, an estimated $5.65K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Coherus Oncology in Q3 2015 and held it in 22 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Coherus Oncology position peaked at $420K in Q3 2019.
  • 135 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.